Detalhe da pesquisa
1.
Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
Oncologist
; 28(1): 72-79, 2023 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36124890
2.
Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.
Future Oncol
; 18(10): 1219-1234, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34939424
3.
Treatment Patterns and Adverse Event-Related Hospitalization Among Patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non-small Cell Lung Cancer After Treatment with EGFR Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy Regimens.
Drugs Real World Outcomes
; 10(4): 531-544, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37659039
4.
Burden of Herpes Zoster Among Patients with Psoriasis in the United States.
Dermatol Ther (Heidelb)
; 13(11): 2649-2668, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37740149
5.
Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States.
J Manag Care Spec Pharm
; 28(4): 449-460, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34958235
6.
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis.
Leukemia
; 36(8): 2108-2120, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35790816